EGFR与VEGFR-2在非小细胞肺癌中的临床意义及相关性分析

发布时间：2018-01-20 08:44

  本文关键词： 非小细胞肺癌 血管内皮生长因子受体 表皮生长因子受体　出处：《中国人民解放军医学院》2016年硕士论文　论文类型：学位论文

【摘要】：目的 本实验主要研究非小细胞肺癌(NSCLC)患者中,EGFR与VEGFR-2基因的mRNA表达水平及EGFR突变情况,总结其与非小细胞肺癌患者临床病理特征之间的关系,并分析基因表达水平之间的相关性,探讨EGFR信号通路与VEGF/VEGFR信号通路的机制,为NSCLC患者合理使用抗表皮生长因子受体和抗血管生成靶向药物联合治疗提供一定的理论依据。方法 统计解放军总医院胸外科2014年至2015年共计128例确诊非小细胞肺癌患者,记录患者年龄、性别、吸烟史、病理类型、分化程度、TNM分期等相关临床资料信息。取样手术新鲜标本肿瘤组织或CT引导下经皮肺肿瘤穿刺的肿瘤组织,使用液相芯片技术对肿瘤细胞的EGFR E18-21基因突变情况和EGFR、 VEGFR-2基因的mRNA表达水平进行定量检测,应用SPSS19.0统计软件对所得数据进行分析,统计有无相关性。结果本组患者EGFR基因突变率为47.7%,其中E1 9基因突变率为21.1%,E21基因的突变率为26.6%,无E18及E20基因突变。EGFR E19基因突变与吸烟史呈现显著相关性(r=0.238, p0.01), EGFR E21基因发生突变与肿瘤病理类型(r=-0.213,p0.05)和肿瘤分化程度(r=-0.190,p0.05)都呈现相关性。EGFR基因表达与肿瘤病理类型相关(r=0.244,p0.01)。VEGFR-2的基因表达与肿瘤病理类型(r=0.271,p0.01)和肿瘤分化程度(r=0.237,p0.01)都呈现相关性。EGFR与VEGFR-2的基因表达显著相关(r=0.320,p0.01)。结论EGFR突变好发于19、21外显子,其中无吸烟史患者易发生E19突变,肿瘤分化高的腺癌患者易发生E21突变。腺癌患者中的EGFR及VEGFR-2基因表达水平更高,VEGFR-2基因表达水平与肿瘤分化程度正相关。EGFR基因与VEGFR-2基因呈现共表达。
[Abstract]:Objective to investigate the mRNA expression level and EGFR mutation of VEGFR-2 gene in patients with non-small cell lung cancer (NSCLC). To summarize the relationship between EGFR and the clinicopathological features of non-small cell lung cancer, and analyze the correlation between gene expression level, and explore the mechanism of EGFR signaling pathway and VEGF/VEGFR signal pathway. To provide a theoretical basis for the rational use of antiepidermal growth factor receptor and antiangiogenic targeted drugs in patients with NSCLC. A total of 128 patients with non-small cell lung cancer (NSCLC) were diagnosed from 2014 to 2015 in thoracic surgery department of PLA General Hospital. To record the age, sex, smoking history, pathological type, degree of differentiation and TNM staging, and other relevant clinical information. The mutation of EGFR E18-21 gene and the mRNA expression of EGFR and VEGFR-2 genes in tumor cells were quantitatively detected by liquid phase microarray technique. Results the mutation rate of EGFR gene was 47.7% in this group. The mutation rate of E19 gene was 21.1and the mutation rate of E21 gene was 26.6%. No E18 or E20 gene mutation. EGFR E19 gene mutation was significantly correlated with smoking history (0.238, p 0.01). The mutation of EGFR E21 gene was associated with the pathological type of the tumor, r-0.213p0.05) and the degree of differentiation of the tumor, r-0.190. The expression of EGFR gene was correlated with the pathological type of tumor. The gene expression of p0.01n.VEGFR-2 and the pathological type of tumor were 0.271p0.01) and the degree of differentiation was 0.237 (P < 0.05). There was a significant correlation between the gene expression of VEGFR-2 and the gene expression of VEGFR-2. Conclusion the mutation of EGFR is more likely to occur in exon 1921. Among them, E19 mutation was easy to occur in patients without smoking history, and E21 mutation was easy to occur in well-differentiated adenocarcinoma patients. The EGFR and VEGFR-2 gene expression levels in adenocarcinoma patients were higher than those in non-smoking patients. The expression level of VEGFR-2 gene was positively correlated with the degree of tumor differentiation. EGFR gene and VEGFR-2 gene co-expressed.
【学位授予单位】：中国人民解放军医学院
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R734.2
，

本文编号：1447589